HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof).

Abstract
The novel severe acute respiratory syndrome coronavirus 2 is causing a worldwide pandemic that may lead to a highly morbid and potentially fatal coronavirus disease 2019 (COVID-19). There is currently no drug that has been proven as an effective therapy for COVID-19. Several candidate drugs are being considered and evaluated for treatment. This includes clinically available drugs, such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir, which are being repurposed for the treatment of COVID-19. Novel experimental therapies, such as remdesivir and favipiravir, are also actively being investigated for antiviral efficacy. Clinically available and investigational immunomodulators, such as the interleukin 6 inhibitors tocilizumab and sarilumab and the anti-granulocyte-macrophage colony-stimulating factor lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine environment that characterizes severe and critical COVID-19. This review article examines the evidence behind the potential use of these leading drug candidates for the treatment of COVID-19. The authors conclude, based on this review, that there is still no high-quality evidence to support any of these proposed drug therapies. The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19.
AuthorsPrakhar Vijayvargiya, Zerelda Esquer Garrigos, Natalia E Castillo Almeida, Pooja R Gurram, Ryan W Stevens, Raymund R Razonable
JournalMayo Clinic proceedings (Mayo Clin Proc) Vol. 95 Issue 7 Pg. 1454-1466 (07 2020) ISSN: 1942-5546 [Electronic] England
PMID32561148 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antiviral Agents
  • Immunologic Factors
Topics
  • Antiviral Agents (therapeutic use)
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections (complications, drug therapy, therapy)
  • Humans
  • Immunization, Passive
  • Immunologic Factors (therapeutic use)
  • Pandemics
  • Pneumonia, Viral (complications, therapy)
  • SARS-CoV-2
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: